Açık Akademik Arşiv Sistemi

Browsing WOS İndeksli Yayınlar Koleksiyonu / WOS Indexed Publications Collection by Author "Dal, Mehmet Sinan"

Browsing WOS İndeksli Yayınlar Koleksiyonu / WOS Indexed Publications Collection by Author "Dal, Mehmet Sinan"

Sort by: Order: Results:

  • Convalescent plasma therapy in patients with COVID-19 
    Altuntas, Fevzi; Ata, Naim; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, Sinem; Basturk, Abdulkadir; Hacibekiroglu, Tuba (PERGAMON-ELSEVIER SCIENCE LTD, 2021)
    Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ...
  • Convalescent plasma therapy in patients withCOVID-19 
    Yigenoglu, Tugce Nur; Hacibekiroglu, Tuba; Berber, Ilhami; Dal, Mehmet Sinan; Basturk, Abdulkadir; Namdaroglu, Sinem; Korkmaz, Serdal; Ulas, Turgay; Dal, Tuba; Erkurt, Mehmet Ali; Turgut, Burhan; Altuntas, Fevzi (WILEY, 2020)
    There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ...
  • COVID-19 in hematopoietic cell transplant recipients 
    Altuntas, Fevzi; Ata, Naim; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, Sinem; Basturk, Abdulkadir; Hacibekiroglu, Tuba; Dogu, Mehmet Hilmi; Berber, Ilhami; Dal, Kursat; Erkurt, Mehmet Ali; Turgut, Burhan; Ulgu, Mustafa Mahir; Celik, Osman; Akunal, Abdullah; Birinci, Suayip (SPRINGERNATURE, 2021)
    In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A ...
  • Inferior prognosis in poor mobilizing myeloma patients 
    Yigenoglu, Tugce Nur; Basci, Semih; Ulu, Bahar Uncu; Bakirtas, Mehmet; Kilinc, Ali; Sahin, Derya; Darcin, Tahir; Yildiz, Jale; Baysal, Nuran Ahu; Iskender, Dicle; Cakar, Merih Kizil; Dal, Mehmet Sinan; Hacibekiroglu, Tuba; Altuntas, Fevzi (PERGAMON-ELSEVIER SCIENCE LTD, 2020)
    Introduction: Induction treatment followed by autologous stem cell transplantation (ASCT) has been accepted as the standard treatment for multiple myeloma (MM) patients. Granulocyte colony stimulating agent (G-CSF), ...
  • Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors 
    Basci, Semih; Ata, Naim; Altuntas, Fevzi; Yigenoglu, Tugce Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, Sinem; Basturk, Abdulkadir; Hacibekiroglu, Tuba; Dogu, Mehmet Hilmi; Berber, Ilhami; Dal, Kursat; Erkurt, Mehmet Ali; Turgut, Burhan; Caglayan, Murat; Ayvali, Mustafa Okan; Celik, Osman; Ulgu, Mustafa Mahir; Birinci, Suayip (SAGE PUBLICATIONS LTD, 2020)
    Introduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with ...
  • Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey 
    Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Besisik, Sevgi; Yenerel, Mustafa Nuri; Celik, Serhat; Kaynar, Leylagul; Yucel, Orhan Kemal; Deveci, Burak; Sonmez, Mehmet; Mehtap, Ozgur (SPRINGER, )
    Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ...
  • Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey 
    Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Besisik, Sevgi; Yenerel, Mustafa Nuri; Celik, Serhat; Kaynar, Leylagul; Yucel, Orhan Kemal; Deveci, Burak; Sonmez, Mehmet; Mehtap, Ozgur (SPRINGER, 2023)
    Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ...
  • Recovery of Symmetrical Peripheral Gangrene of Limbs in a Patient After Performing Hemoadsorption in Septic Shock 
    Ulu, Bahar Uncu; Yigenoglu, Tugce Nur; Hacibekiroglu, Tuba; Saglam, Dursun Ali; Kilinc, Ali; Iskender, Gulsen; Cakar, Merih Kizil; Dal, Mehmet Sinan; Altuntas, Fevzi (WILEY, 2021)
    We report a 42-year-old patient who had Hodgkin lymphoma and developed bilateral symmetrical peripheral gangrene (SPG) in the feet and hands, which occurred during septic shock after autologous hematopoietic stem-cell ...
  • The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors 
    Yigenoglu, Tugce Nur; Basci, Semih; Bakirtas, Mehmet; Ulu, Bahar Uncu; Kilinc, Ali; Sahin, Derya; Darcin, Tahir; Yildiz, Jale; Merdin, Alparslan; Baysal, Nuran Ahu; Iskender, Dicle; Cakar, Merih Kizil; Dal, Mehmet Sinan; Hacibekiroglu, Tuba; Altuntas, Fevzi (PERGAMON-ELSEVIER SCIENCE LTD, 2020)
    Introduction: Peripheric blood derived stem cells are used in 75 % of allogeneic stem cell transplantations. Iron, vitamin B12 and folate involve in hematopoiesis. Therefore serum levels of iron, vitamin B12 and folat may ...
  • The outcome of COVID-19 in patients with hematological malignancy 
    Yigenoglu, Tugce N.; Ata, Naim; Altuntas, Fevzi; Basci, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, Sinem; Basturk, Abdulkadir; Hacibekiroglu, Tuba; Dogu, Mehmet H.; Dal, Kursat; Erkurt, Mehmet A.; Turgut, Burhan; Ulgu, Mustafa Mahir; Celik, Osman; Imrat, Ersan; Birinci, Suayip (WILEY, 2021)
  • The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL 
    Akpinar, Seval; Dogu, Mehmet Hilmi; Celik, Serhat; Ekinci, Omer; Hindilerden, Ipek Yonal; Dal, Mehmet Sinan; Davulcu, Eren Arslan; Tekinalp, Atakan; Hindilerden, Fehmi (2022)
    We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least ...